BUSINESSAug 4 · 20:17 UTCMARKETWATCHJaimy Lee

Novo Nordisk stock is sliding again — and the Wegovy pill’s surprise miss is partly to blame

Novo Nordisk stock is declining due to the underperformance of its Wegovy pill, though the company reported an improved annual outlook. The Danish drugmaker attributed the stock slide partly to the pill's unexpected results.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Novo NordiskorganizationWegovytopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSMay 6 · 07:25 UTC
Novo Nordisk says the Wegovy pill saw the fastest take-up in weight-loss drug history
BUSINESSJul 31 · 13:54 UTC
Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
BUSINESSAug 4 · 16:48 UTC
Novo Nordisk Slides as Forecast Boost Fails to Impress
BUSINESSMay 6 · 13:34 UTC
STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
BUSINESSAug 4 · 17:41 UTC
Novo Nordisk is raising its full-year outlook as its weight loss pill keeps selling
BUSINESSMay 6 · 06:46 UTC
Wegovy pill sales smash forecasts after launch as Novo Nordisk hikes guidance